HMG-CoA Reductase Inhibitors (Milestones in Drug Therapy)

HMG-CoA reductase inhibitors (statins) are established drugs for the treatment of hypercholesterolemia. Furthermore, they induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. This book deals with statins which have substantially altered the approach to therapy of atherosclerosis and its sequelae. Emphasis is placed on the scientific background to the discoveries and the development of the therapy, including an overview of the current state of knowledge of the drugs. Clinical data are reviewed extensively. This book not only provides the reader with valuable information but also stimulates further research into the pathogenesis of atherosclerosis and the mechanisms behind the action of effective statins. It sets the stage for creative thinking among scientists of many disciplines for the accomplishment of our ultimate goals in treating atherosclerosis and its sequelae. This topical volume, written by the leaders in the field, will appeal to medical reseachers, members of the pharmaceutical industry, physicians and all those interested in this latest frontier of treatment of hypercholesterolemia.

Publisher: Birkhauser Verlag AG

Published: Switzerland, 23 October 2002

Format: Hardback, 151 pages

Age Range: 15+

Other Information: X, 151 p.

Dimensions: 23.4 x 15.6 x 1.1 centimeters (0.58 kg)

Writer: Gerd Schmitz, Michael Torzewski

Table of ContentsList of contributors. Preface. Stefano Bellosta, Rodolpho Paoletti, Alberto Corsini: History and development of HMG-CoA reductase inhibitors. Margaret E. Brousseau and Ernst J. Schafer: Structure and mechanisms of action of HMG-CoA reductase inhibitors. Joerg Kotzka, Wilhelm Krone and Dirk Muller-Wieland: Sterol-regulatory element binding proteins (SREBPs): gene regulatory target of statin action. Gerd Schmitz and Michael Torzewski: Cellular effects of HMG-CoA reductase inhibitors on blood cells (monocytes, macrophages, platelets). Koichi Node and James K. Liao: Effects of HMG-CoA reductase inhibitors on cells of the vascular wall - pleiotropic effects of HMG-CoA reductase inhibitors. Hans-Peter Thomas and Elisabeth Steinhagen-Thiessen: Indications and contraindications for statin treatment (primary and secondary prevention of hypercholesterolemia). Helena K. Gylling and Tatu A. Miettinen: Clinical experience: studies with HMG-CoA reductase inhibitors. C. Berry, A. Davie and J. McMurray: Cost-effectiveness of statins in primary and secondary prevention of coronary heart disease. Index